Caspar Foghsgaard, Author at Vaccibody.com

January 27, 2020 VACCIBODY REGISTRATION AND TRADING ON NOTC

Posted at 00:40h in quarterly-reports

Vaccibody AS will be registered on the NOTC-list as of January 27, 2020...

December 13, 2019 CALL FOR EXTRAORDINARY GENERAL MEETING

Posted at 15:41h in quarterly-reports

Call for extraordinary general meeting 20 December 2019...

November 2, 2019 VACCIBODY TO HOST CAPITAL MARKETS DAY IN OSLO ON 12TH NOVEMBER 2019

Posted at 18:05h in Uncategorized

Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, will host its capital markets day on November 12 and is pleased to invite investors, analysts and press to presentations by the members of the company’s executive management...

October 11, 2019 VACCIBODY APPOINTS NEW CHIEF MEDICAL OFFICER

Posted at 07:34h in Uncategorized

SIRI TORHAUG, MD APPOINTED AS NEW CHIEF MEDICAL OFFICER...

October 7, 2019 VACCIBODY AS TO PRESENT DATA ON VB10.NEO AT UPCOMING SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING 2019

Posted at 13:35h in Uncategorized

VACCIBODY WILL PRESENT PRELIMINARY SAFETY, EFFICACY AND IMMUNOGENICITY RESULTS FROM ITS PHASE 1/2A (DIRECT-01) STUDY OF CANCER NEOANTIGEN VACCINE VB10.NEO IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS...

August 28, 2019 ORGANIZATIONAL CHANGES IN VACCIBODY

Posted at 14:26h in Uncategorized

VACCIBODY ANNOUNCES MARTIN BONDE TO STEP DOWN AS CHIEF EXECUTIVE OFFICER, MICHAEL ENGSIG TO TAKE OVER...

August 15, 2019 ORGANIZATIONAL CHANGES IN VACCIBODY

Posted at 09:36h in Uncategorized

VACCIBODY APPOINTS MICHAEL ENGSIG AS CHIEF OPERATING OFFICER...

August 14, 2019 QUARTERLY REPORT – 2019 Q2

Posted at 09:01h in Uncategorized

Vaccibody - Quarterly report 2019 Q2...

May 24, 2019 QUARTERLY REPORT – 2019 Q1

Posted at 21:30h in Uncategorized

Vaccibody - Quarterly report 2019 Q1...

March 25, 2019 POSITIVE 12-MONTH RESULTS FROM PHASE IIa CLINICAL STUDY IN HIGH GRADE CERVICAL DYSPLASIA PROVIDES PROOF-OF-CONCEPT FOR VACCIBODY’S IMMUNOTHERAPY PLATFORM AND LEAD CANDIDATE VB1O.16

Posted at 10:00h in Uncategorized

Oslo, March 25, 2019 Vaccibody AS today announced positive 12-month results from the phase IIa part of the clinical study VB C-01. This study is a first human dose, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial...